Google Deepmind has unveiled the third major version of its “AlphaFold” artificial intelligence model, designed to help scientists design drugs and target disease more effectively.
In 2020, the company made a significant advance in molecular biology by using AI to successfully predict the behaviour of microscopic proteins.
With the latest incarnation of AlphaFold, researchers at DeepMind and sister company Isomorphic Labs—both overseen by cofounder Demis Hassabis—have mapped the behaviour for all of life’s molecules, including human DNA.
The interactions of proteins—from enzymes crucial to the human metabolism, to the antibodies that fight infectious diseases—with other molecules is key to drug discovery and development.
DeepMind said the findings, published in research journal Nature on Wednesday, would reduce the time and money needed to develop potentially life-changing treatments.
“With these new capabilities, we can design a molecule that will bind to a specific place on a protein, and we can predict how strongly it will bind,” Hassabis said in a press briefing on Tuesday.
“It’s a critical step if you want to design drugs and compounds that will help with disease.”
The company also announced the release of the “AlphaFold server”, a free online tool that scientists can use to test their hypotheses before running real-world tests.
Since 2021, AlphaFold’s predictions have been freely accessible to non-commercial researchers, as part of a database containing more than 200 million protein structures, and has been cited thousands of times in others’ work.
DeepMind said the new server required less computing knowledge, allowing researchers to run tests with just a few clicks of a button.
John Jumper, a senior research scientist at DeepMind, said: “It’s going to be really important how much easier the AlphaFold server makes it for biologists—who are experts in biology, not computer science—to test larger, more complex cases.”
Dr Nicole Wheeler, an expert in microbiology at the University of Birmingham, said AlphaFold 3 could significantly speed up the drug discovery pipeline, as “physically producing and testing biological designs is a big bottleneck in biotechnology at the moment”.
—Martin Coulter, Reuters
Melden Sie sich an, um einen Kommentar hinzuzufügen
Andere Beiträge in dieser Gruppe
Most of us are used to using internet chatbots like ChatGPT and
Intel‘s promised $28 billion chip fabrication plants in Ohio are facing further delays, with the first factory in New Albany expected
TikTok and Instagram are flooded with reels of food influencers hyping already viral restaurants or bringing hundreds of thousands of eyes to hidden gems. With sauce-stained lips, exaggerated chew
An unsubstantiated online theory has recently taken hold, claiming that family vloggers are fleeing Los Angeles to escape newly introduced California laws designed to protect children featured in
At a press conference in the Oval Office earlier this month, Elon Musk—a billionaire who is not, at least formally, the President of the United States—was asked how the Department of Government Ef
Last Energy, a nuclear upstart backed by an Elon Musk-linked venture capital fund, says it plans to construct 30 microreactors on a site in Texas to supply electricity to data centers across the s
Democratic lawmakers demanded answers from billionaire Elon Musk’s Department of Govern
